Sign In
Buy SPRB
$49.05
-0.250 (-0.507%)
At Close: Jun 03, 2026
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
04:05pm, Thursday, 14'th Aug 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Announces Reverse Stock Split
04:01pm, Thursday, 24'th Jul 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder
10:31am, Tuesday, 22'nd Jul 2025
Study Initiation Marks Key Milestone in Advancing Precision Psychiatry Treatment for Major Depressive Disorder Topline Results Anticipated in the First Half of 2026 MUNICH, Germany and SOUTH SAN FRANC
Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market
08:00am, Thursday, 12'th Jun 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
04:01pm, Tuesday, 06'th May 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological di
Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)
05:27pm, Tuesday, 15'th Apr 2025
Spruce Biosciences, Inc. (NASDAQ:SPRB ) Corporate Update Conference Call April 15, 2025 8:30 AM ET Company Participants Samir Gharib - President and CFO Javier Szwarcberg - CEO Kirk Ways - Chief Medic
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
01:06pm, Friday, 13'th Dec 2024
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
08:21am, Wednesday, 11'th Dec 2024
On Tuesday, Spruce Biosciences, Inc. SPRB revealed topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH.
Spruce Biosciences to wind down investment for genetic disorder drug
04:14pm, Tuesday, 10'th Dec 2024
Spruce Biosciences said on Tuesday it will wind down investments for its genetic disorder drug after it failed to meet the main goal in a mid-stage study.
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
04:01pm, Tuesday, 10'th Dec 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates
10:11am, Monday, 11'th Nov 2024
Spruce Biosciences, Inc. (SPRB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.30 per share a year ago.
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscie
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
11:00am, Sunday, 03'rd Nov 2024
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscie
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Take Part
11:00am, Saturday, 02'nd Nov 2024
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscie
